|
1kit (10Vial) .
| Ɔmɔs: | |
|---|---|
▎ Ipamorelin Strukchɔ
Sos: PubChem |
Sikyɔn: XHXFK Mɔlikul Fɔmula: C 38H 49N 9O5 Molikul Weyt: 711,9 g/mol CAS Nɔmba: 170851-70-4 PubChem CID: 9831659. Di wan dɛn we de wok Sinonim dɛn: NNC-26-0161;UNII-Y9M3S784Z6;IPAMƆRƐLIN ASƐTƐT |
▎ Ipamorelin Risach
Wetin na di risach bakgrɔn fɔ Ipamorelin?
Dilɛy fɔ ɛmti di bɛlɛ na wan kɔmɔn kɔndishɔn, ɛn naw, na smɔl tritmɛnt opshɔn dɛn de we go wok fayn. Risach dɔn sho se Ipamorelin, as sεntetik peptidomimetic, de akt pan di ghrelin rεsεpכta εn i kin gεt tεrapi ifekt pan dilay gastric εmpty. insay wan stכdi pan wan rodεnt mכdel fכ gastroparesis, gεstroparesis bin indyuz bay abdominal כpεrayshכn εn intestinal manipulεshכn, εn dεn fכnshכn se Ipamorelin kin aksεlεrayt gastric εmpti [1]..
Postoperative ileus na wan signifyant chalenj in klinik praktis, we nɔ gɛt ifektiv manejmɛnt strateji. di ghrelin risεptor stimulashכn gεt mכtiliti-prכmot ifekt pan כl tu di כp εn lכw pat dεm na di gεstrointestinal trakt. as ghrelin rεsεptכr agonist, Ipamorelin gεt pכtεnshal aplikεshכn valyu in di tritmεnt fכ postכpεraytiv ileus. Fɔ ɛgzampul, insay wan stɔdi, dɛn bin du wan prospektiv, randomized, kɔntrol pruf-ɔf-kɔnsɛpt stɔdi pan pasɛnt dɛn we dɛn de du intestinal rɛsekshɔn afta dɛn dɔn ɔpreshɔn dɛn bɛlɛ fɔ ebul fɔ no if Ipamorelin sef ɛn if i wok [2]..
ipamorelin de pan di growth homon releasing peptides (GHRPs), we na sεntetik pεntapεptida we ebul fכ mek di growth כmon kכmכt frכm di haypothalamus εn pituitary gland. di כmon we de gro de ple imכtant rol fכ di bכdi in gכd, rεpa, εn mεtabolism, so di rol we Ipamorelin de du fכ rεgεl di gכt hכmon dεn dכn atrak bכku bכku atεnshכn bak [3]..
biכs fכ in pכtεnshal valyu fכ trit dilay gεstrik εmpti, postכpεraytiv ileus, εn in rol as gכt hכmon rilis pεptida, Ipamorelin dכn atrak bכku risach atεnshכn.
Wetin na di we aw Ipamorelin de wok?
1. Fכ mek di כmon we de mek di gכt de kכmכt:
Ipamorelin de pan di growth homon releasing peptides (GHRPs), we kin mek di growth homon de rilis frכm di haypothalamus εn pituitary gland. in vitro εn in vivo εkspεriεns, Ipamorelin dכn sho hכy pכtεns εn efikכs fכ rilis gכt כmon. fכ egzampl, insay wan stכdi, di pכtεns εn efikכs fכ Ipamorelin fכ rilis gכt hכmon frכm praymari rat pituitary sεl dεm bin sεm lεk di wan dεm fכ GHRP-6 [3] . i mεkanism fכ akshכn na fכ stimulate di rilis fכ di gכt כmon bay we i de aktibכt GHRP-lεk rεsεpכta dεm. tru fכmakכlכjik analisis, dεn kכnfכm se lεk GHRP-6, Ipamorelin de stimulate di rilis fכ di gכt כmon tru GHRP-lεk rεsεpכta dεm.
2. Ifekt pan di gastrointestinal trakt
Fɔ mek di gastric ɛmti kwik kwik wan:
insay rodεnt mכdel, Ipamorelin kin aksεlεrayt gastric εmpti. כpεrayshכn na di bכdi de mek di gεstrik εmpti delay, bכt afta dεn gi di Ipamorelin (0.014 μmol/kg insay di bכdi), di gεstrik εmpti de aksεlεrayt bכku bכku wan. Ipamorelin de stimulat gastric kontraktiliti εn aksεlεrayt gastric εmpty tru wan mεkanism we di aktibכshכn fכ di ghrelin rεsεptכr de mεdiet, we involv cholinergic excitatory nyuron dεm (Greenwood-Van Meerveld B, 2012).
Impruv di simptom dɛm fɔ di ileus afta dɛn dɔn ɔpreshɔn:
insay rodεnt mכdel dεm fכ postכpεraytiv ileus, Ipamorelin kin impruv di simptom dεm. Afta we dɛn gi Ipamorelin afta dɛn dɔn du di ɔpreshɔn, wan doz fɔ Ipamorelin (1mg/kg) ɔ GHRP-6 (20μg/kg) kin ridyus di tɛm we dɛn kin gi fɔ di fɔs defekeshɔn. if yu gi am Ipamorelin (0.1 כ 1mg/kg) i kin bכku bכku wan inkrεs di kumulativ fεkal autput, it intake, εn weit gεn [4]..
3. Efεkt dεm pan insulin sekreshכn
Ipamorelin kin mek insulin sekreshכn na di pankrεas tisu fragmεnt dεm fכ nכmal εn dayabεtik rat dεm. di inkrεs pan insulin sekreshכn we Ipamorelin indyuz kin sכmtεm inhεbit bay diltiazem, yohimbine, propranolol, כ wan kכmbaynshכn fכ atropine, propranolol, εn yohimbine. pan dayabεtik rat, atropin kin ridyus di insulin sekreshכn we Ipamorelin de mek, bכt dis ifekt nכ de si pan nכmal rat. dis sho se Ipamorelin de mek insulin rilis tru di kalsiכm chεnal εn di adrenergic rεsεpכta path dεm [5] ..
4. Fɔ mek pɔsin nɔ fil pen
insay εkspεriεns mכdel dεm fכ nכn-inflammatory vishכral haypasεnsitiviti εn somatik mεkanikal allodynia, Ipamorelin, as pεrifεral rεstrikt ghrelin rεsεptכr agonist, kin ridyus kכlon haypasεnsitiviti εn somatik allodynia bכku bכku wan. di mεkanism fכ akshכn na di ghrelin rεsεpכta de mεdiet am, εn dis antinociceptiv ifekt kin blכk bay di ghrelin rεsεpכta antagonist H0900 [6] ..
s aw di ifekt we ipamorelin de gi pan insulin sekreshכn frכm pankrεas tisu fragmεnt dεm fכ nכmal εn dayabεtik rat dεm.
Sos:PubMed [5] we dɛn pul am.
Wetin na di aplikeshɔn dɛn fɔ Ipamorelin?
1. Fɔ mek di ɔmon we de gro na di bɔdi kɔmɔt
di ipamorelin kin mek di hכmon we de gro fכ kכmכt frכm di haypothalamus εn di pituitary gland. di כmon we de gro de ple imכtant rol na di mכtalman bכdi, inklud fכ mek di protin dεm, fכ mek di sεl dεm bכku, εn fכ mek di tisu rεpa. So, dεn kin yuse Ipamorelin fכ trit di gכt hכmon dεm כ כda sik dεm we gεt fכ gכt hכmon dεm [7]..
2. Fɔ mek di bɔdi wok fayn fayn wan
Fɔ mek di gastric ɛmti kwik kwik wan:
insay rodεnt mכdel dεm, Ipamorelin de aksεlεrayt gastric εmpty in mכdel dεm fכ postכpεraytiv ileus tru wan mεkanism we de mεdiet bay di aktibכshכn fכ di gכt hכmon we de rilis pεptida rεsεptכr, we involv cholinergic excitatory nyuron dεm [1] . כpεrayshכn na di bכdi kin mek di gεstrik εmpti delay, εn if dεn gi am Ipamorelin i kin ridyus di prכpכshכn fכ di it we de rεsidεnt na di bεlε bכku bכku wan, we kin mek di gεstrik mכtiliti bכku.
fכ mek di gεstrointestinal pεristalsis:
insay rodεnt mכdel dεm fכ postכpεraytiv ileus, Ipamorelin kin impruv di simptom dεm fכ di sik pipul dεm. fכ egzampl, insay rat mכdel, Ipamorelin kin rεdכks di tεm fכ fכs fכ fכs afta dεn כpεrayshכn, inkrεs fεkal autput, it, εn weit gεt [4] . ripit administreshכn fכ Ipamorelin kin sכmtεm inkrεs di kumulativ fεkal autput, it intake, εn weit gεn, we sho se i pכsitiv rεgεdyushכn ifekt pan gεstrointestinal fכnshכn.
3. Fɔ mek pɔsin nɔ fil pen
Fɔ pul di vishɛl ɛn somatik pen:
Risach sho se Ipamorelin, as growth homon we de rilis pεptida rεsεptכr agonist, gεt antinociceptive prכpati dεm. insay εkspεriεns mכdel dεm we nכ gεt kכlon εpitεlial inflameshn, Ipamorelin kin sכmtεm ridyus nכn-inflammatory visceral haypasεnsitiviti εn somatik mεkanikal allodynia [6]..
in mεkanism fכ akshכn kin bi mεdiet bay di gכt hכmon we de rilis pεptida rεsεpכta, we de tek pat pan di rεguleshכn fכ di vishכral εn somatik haypasεnsitiviti, we de gi wan pכtεnshal nyu mεtכd fכ di tritmεnt fכ akyu vishכnal εn somatik pen.
Wetin na di risach prɔgrɛs fɔ Ipamorelin fɔ trit di growth ɔmon dɛfisiɛns?
di כmon we de gro na di sik we de kכz we di hכmon we de gro fayn fayn wan frכm di antεriכr pituitary gland, we kin afekt di growth εn divεlכpmεnt fכ pikin dεm εn di bכdi mεtabolism fכ big pipul dεm. Insay di las ia, Ipamorelin, as growth ɔmon sekretagog, dɔn atrak bɔku pipul dɛn atɛnshɔn fɔ trit di growth ɔmon dɛfisiɛns. Dis na di rilevɛns risach prɔgrɛs fɔ Ipamorelin fɔ trit di growth ɔmon dɛfisiɛns.
1. di stimulating ifekt we Ipamorelin de gi pan di growth homon sekreshכn
Ipamorelin kin mek di ɔmon we de gro na di bɔdi kɔmɔt. Risach sho se Ipamorelin kin wok togɛda wit di ɔmon we de rilis di ɔmon we de gro (GHRH) fɔ mek di ɔmon we de gro fayn fayn wan [8] . insay animal εkspεriεns, afta 21 dez we dεn tek tritmεnt wit Ipamorelin insay yכng uman rat dεm, we dεn kכmpεr wit di kכntrol grup, di basal gכt hכmon rilis insay di monolayer kכltכr fכ di pituitary sεl dεm inkrεs. di sem tεm, Ipamorelin εn GHRH kin mek di rilis fכ di gכt כmon frכm di kכlt pituitary sεl dεm in vitro. כltu, insay di GHRH prεtritmεnt grup, di sכbsεkshכn gכt כmon rεspכns to stimulashכn nכ bin εnhans, we insay di Ipamorelin prεtritmεnt grup, nכ dis kayn dεsensitayzεshכn fεnomen bin de, we sho se Ipamorelin nכ de lid to dεsensitayzεshכn fכ di gכt hכmon rεspכns insay yכng uman rat dεm [8]..
2. Di ifekt we Ipamorelin gɛt pan di wet we pɔsin de gɛt
If yu gi Ipamorelin fɔ lɔng tɛm, dat kin mek yu yɔŋ uman rat dɛn wet go ɔp fayn fayn wan. di monitarin we dεn de mכnitor evride sho se di pasεnshכn fכ di wet we di Ipamorelin prεtritmεnt grup εn di GHRH prεtritmεnt grup hכy pas di wan we de na di kכntrol grup [8] . dis riliyt to di fact se Ipamorelin de mek di sekreshכn fכ di growth כmon, we in tכn de mek di protin sεntez εn sεl gro.
3. Di ifekt we Ipamorelin gɛt pan bon fɔmɛshɔn
insay wan adכlt rat mכdel, dεn fכnshכn se di gכt hכmon sekretagכg Ipamorelin kin kכntrכl di katabolik ifekt dεm we glukokortikoyd (GC) de gi pan skel mכsul εn bon. we yu kכmpεr wit di grup we dεn injεkt wit GC nכmכ, insay di animal dεm we dεn injεkt wit כl tu di GC εn Ipamorelin, di maksimal tεtanik tεnshכn fכ di kכlf mכsul inkrεs bכku bכku wan, εn di pεriostεal bon fכmeshכn rεt inkrεs fכ tכl [8, 9] . dis sho se Ipamorelin gεt fayn ifekt fכ mεnten di mכsul dεm trεnk εn fכ mek di bon fכm, εn i kin εp fכ mek dεn nכ gεt kכmplikεshכn lεk כstioporosis pan pasεn dεm we nכ gεt gכt hכmon dεm.
4. Di ifekt we Ipamorelin gɛt pan di gastrointestinal wok
as selektiv growth hכmon-rilis כmon agonist εn growth כmon-rilis pεptida rεsεptכr agonist, Ipamorelin dכn sho tεrapi efikכs in wan maws mכdel fכ postכpεraytiv intestinal paralayz. singl administreshכn fכ Ipamorelin כ growth hormone-releasing peptide (GHRP)-6 sכt di tεm to di fכs postכpεraytiv bכwel muvmεnt, bכt i nכ bin gεt nכ ifekt pan kumulativ fεkal autput, it intake, כ weit gεn. Ipamorelin de mek di kumulativ fekal autput, it intake, ɛn weit go ɔp. dis sho se Ipamorelin kin gεt sכm rol fכ impruv di gεstrointestinal fכnshכn εn i kin εp fכ impruv di dijestiv εn absכptiv fכnshכn pan di sik pipul dεm we gεt gכt hכmon dεfichεns. [4] ..
fכ sכmari, as sεlektiv gכt hכmon sekreshכn prכmotεr, Ipamorelin de efyushכn stimulate di rilis fכ gכt hכmon bay we i de aktibכt di gכt hכmon-rilis pεptida rεsεpכta (GHS rεsεptכr), we nכ de afekt di lεvεl dεm fכ adrenocorticotropic homon (ACTH) εn kכtisol bכku bכku wan. di wok dεm we i de du na fכ mek di כmon dεm we de gro, fכ rεgεl di gεstrointestinal mכtiliti, εn fכ sכm pen. i ay selektiviti εn mכlti-target kכntribyushכn dεm de gi klinik aplikεshכn pכtεnshal, we de mek i fayn fכ yus insay kכndishכn dεm lεk growth כmon dεfisiεns, postכpεraytiv intestinal obstrכkshכn, εn pen mεnejmεnt.
Bɔt di pɔsin we rayt di buk
Di tin dɛn we wi dɔn tɔk bɔt ɔp, na ɔl di tin dɛn we Cocer Peptides dɔn du risach, ɛdit ɛn kɔmpilayt.
Sayɛns Jɔnal Author
Raun K na wan risachman we gɛt fɔ du wit di Tɛknikal Yunivasiti ɔf Denmak (DTU) ɛn di Novo Nɔdisk Fɔdayshɔn. In risach intɛres dɛn span bɔku disiplin dɛn, lɛk Ɛndokrinɔlɔji & Mɛtabolism, Ɔtopɛdiks, Nyutrishɔn & Daytɛtiks, Veterinari Sayns, ɛnƐnjinia. Bɔku tɛm, in wok kin pe atɛnshɔn pan di divɛlɔpmɛnt fɔ sataynabul ɛn inovativ sɔlvishɔn, mɔ insay di kɔntɛks fɔ bayɔteknɔlɔji ɛn bayɔ-bɛs ikɔnomi.
Raun K dɔn kɔntribyut to prɔjek dɛm we gɛt fɔ du wit di Novo Nordisk Fɔdayshɔn Sɛntral fɔ Bayosastaynabiliti na DTU, we de dediket fɔ advans sɛl faktri dizayn, mɛtabolik injinɛri, ɛn sɛntetik bayoloji fɔ sataynabul bayɔprodakshɔn. Apat frɔm dat, i dɔn involv insay risach initiativs we dɛn aim fɔ ridyus di rilayns pan fɔshal-bɛs matirial ɛn fɔ protɛkt grɛn transishɔn tru bayɔprodakshɔn sɔlvishɔn.
In wok de tɔch bak pan injinɛri aplikeshɔn dɛn, lɛk di divɛlɔpmɛnt fɔ katalis ɛn bayɔprosɛs fɔ industrial ɛn envayrɔmɛnt sastaynabiliti. Raun K in intadisiplinari aprɔch de brij sayɛns risach ɛn prɛktikal aplikeshɔn, we de mek impɔtant kɔntribyushɔn to ɔl tu di akademik ɛn industrial sɛktɔ. Raun K de list in di rεfrεns כf saytεshכn [3].
